Generative AI in Drug Discovery Market: Strategic Insights Through 2030
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Forecasted Market Size Trajectory Of The Generative Artificial Intelligence (AI) In Drug Discovery Market From 2026 To 2030?
The generative artificial intelligence (AI) in drug discovery market has experienced significant expansion in recent years. It is anticipated to increase from $0.25 billion in 2025 to $0.33 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 30.6%. The historical surge can be ascribed to elements like high drug development costs, growth in computational chemistry, the availability of biological datasets, the adoption of machine learning tools, and pharmaceutical r&d investment.
The generative artificial intelligence (AI) in drug discovery market is anticipated to undergo significant expansion in the coming years, with projections indicating a rise to $0.86 billion by 2030, reflecting a robust compound annual growth rate (CAGR) of 27.0%. This expected growth within the forecast period can be credited to the incorporation of generative models into development pipelines, an increasing demand for expedited drug discovery processes, the broadening of biologics optimization efforts, collaborations formed between AI enterprises and pharmaceutical companies, and a reduction in the time-to-market for new drugs. Prominent trends observed during this period are set to include a surge in the adoption of AI-driven molecule generation techniques, enhanced utilization of deep learning in drug design, an expansion of applications for small molecule discovery, increasing integration of AI in lead optimization stages, and the acceleration of early-stage drug development.
Access Your Free Sample Report For In-Depth Market Analysis:
What Leading Drivers Are Supporting The Generative Artificial Intelligence (AI) In Drug Discovery Market Expansion?
An increasing number of clinical trials is anticipated to boost the expansion of generative AI within the drug discovery market. These trials utilize human participants to evaluate the safety and efficacy of novel medical interventions, collecting scientific evidence regarding their applicability for human use. The growing volume of clinical trials stems mainly from progress in medical research, a higher incidence of diseases, evolving regulations, the worldwide nature of clinical investigation, patient support and understanding, industry rivalry, technological breakthroughs, and available financial support. Information from clinical trials empowers generative AI models, accelerating drug discovery through the prediction of molecular interactions and the design of new compounds. This combination facilitates personalized medical approaches, enhances the effectiveness of treatments, leads to better patient results, and transforms the pharmaceutical industry. For example, as reported by Pharmaceutical Technology, a UK-based business news and media firm, in January 2025, 3,213 trials are scheduled to commence this year, with 823 in Phase I and 1,102 in Phase II. Similar to 2024, oncology is projected to maintain its position as the leading therapeutic field, representing 946 trials, trailed by the central nervous system with 686 trials, and then cardiovascular significantly further back with 258 trials. Consequently, the increasing volume of clinical trials is propelling the advancement of generative AI in the drug discovery market.
How Is The Generative Artificial Intelligence (AI) In Drug Discovery Market Segmented Across Different Segment Categories?
The generative artificial intelligence (AI) in drug discovery market covered in this report is segmented –
1) By Type: Small Molecule, Large Molecule
2) By Technology: Deep Learning, Machine Learning, Reinforcement Learning, Molecular Docking, Quantum Computing
3) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutions, Contract Research Organizations (CROs), Other End-Users
Subsegments:
1) By Small Molecule: Drug Design And Optimization, Lead Discovery And Identification, Toxicology Prediction, Molecular Property Prediction, ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction
2) By Large Molecule: Protein Structure Prediction, Antibody Design, Biologics Optimization, Peptide Design, Biopharmaceutical Discovery And Optimization
What Emerging Trends Are Seen In The Generative Artificial Intelligence (AI) In Drug Discovery Market?
Leading companies within the generative AI in the drug discovery market are actively developing sophisticated AI-powered instruments to expedite drug discovery processes. These AI-enabled tools accelerate drug development by optimizing drug discovery, design, and clinical trials through the application of predictive analytics and machine learning. They further enhance efficiency in target identification and compound screening, including virtual screening using AI, preclinical development, regulatory compliance, and manufacturing operations. For instance, in May 2023, Google Cloud, a US-based cloud computing service provided by Google, launched two innovative AI-driven solutions. These solutions, the Target and Lead Identification Suite and the Multiomics Suite, are specifically designed to advance drug discovery and precision medicine across organizations in the biotech, pharmaceutical, and public sectors. The Target and Lead Identification Suite assists researchers in understanding amino acid functions and predicting protein structures, while the Multiomics Suite accelerates the analysis and interpretation of genomic data, thereby simplifying the development of personalized treatments.
Which Organizations Play A Role In The Generative Artificial Intelligence (AI) In Drug Discovery Market Landscape?
Major companies operating in the generative artificial intelligence (AI) in drug discovery market are Bayer AG, NVIDIA Corporation, Merck KGaA, IBM Research, Schrödinger Inc., Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc., MAbSilico, Reverie Labs, Standigm Inc., DeepMatter Group Limited, Variational AI Inc
Get The Full Generative Artificial Intelligence (AI) In Drug Discovery Market Report:
Which Region Has The Greatest Market Share In The Generative Artificial Intelligence (AI) In Drug Discovery Market?
North America was the largest region in the generative AI in drug discovery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Generative Artificial Intelligence (AI) In Drug Discovery Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Generative Artificial Intelligence (AI) In Drug Discovery Market 2026, By The Business Research Company
Lab Automation In Drug Discovery Market Report 2026
Artificial Intelligence In Drug Discovery Market Report 2026
Artificial Intelligence Ai In Biopharmaceuticals Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
